covid_cell_1_20

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | May 19, 2021 | News story | Research and Development |   

The past week has seen lots of positive COVID-19 vaccine news; the Pfizer-BioNTech vaccine can be refrigerated much longer than initially thought, a study has shown that 96% people develop antibodies after just one COVID-19 jab, and a delayed Pfizer vaccine dose by 12 weeks can give 3.5 times more immunity.

 1. Pfizer-BioNTech vaccine can be kept in fridge longer than previously thought – Published 18/05/2021

The EMA has extended the recommended approved storage period for an unopened thawed vial of the Pfizer-BioNTech vaccine from five days to one month.

Advertisement

 2. Major UK study finds 96% people develop antibodies after one COVID-19 jab – Published 18/05/21

 More than 96% of people develop antibodies after just one COVID-19 jab of either AstraZeneca or Pfizer, and almost 100% do after both doses, a UK study has found.

 3. Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows – Published – 14/05/21

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed 12 weeks apart, a Birmingham University study has shown.

 4. India approves Covaxin clinical trials for children aged 2-18 years old – Published 13/05/21

The Drugs Controller General of India (DCGI) has cleared Bharat Biotech’s Covaxin trials on children from 2-18 years old.

 5. Sanofi and GSK’s COVID-19 vaccine shows promising results in Phase II trial – Published 17/05/21

The adjuvanted recombinant COVID-19 vaccine produced by Sanofi and GSK has demonstrated strong immune responses across all adult age groups in its Phase II trial.

Related Content

No items found
The Gateway to Local Adoption Series

Latest content